AEON Biopharma, Inc. — Form 8-K
Filed November 16, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
AEON received FDA Type 2b meeting minutes approving a two-stage comparative pharmacodynamic (CMAP) study design for ABP-450 biosimilar to BOTOX, with IND submitted and Q1 2027 initiation planned. The company expanded analytical evidence to 98% coverage of the neurotoxin sequence (from 93%) and received ~$6.2M gross proceeds from exercising two-year milestone warrants at reduced prices ($0.20/share for common, $0.1999 for pre-funded). Cash position: $11.4M as of Sept 30, 2026, plus $6.2M warrant proceeds, expected to fund operations into Q2 2027.
Why this rating
FDA validation of development pathway and $6.2M capital raise (71% of company market cap) are material for a $8.7M-market-cap biotech. Regulatory clarity reduces execution risk; cash extends runway. However, still pre-IND initiation phase with execution risk.
Tradability signal
NO TRADE
No trade: price $0.16 is below our $0.5 floor — spreads at this level eat any edge. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $0.14 ▼ 9.38% | at our read · unknown $0.16 | +10 min · unknown $0.14 ▼ 8.68% | +30 min · unknown $0.13 ▼ 18.19% | +1 hr · unknown $0.12 ▼ 24.87% | +4 hrs · unknown $0.13 ▼ 19.15% |
The stock had already moved +10.35% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.